Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
TNFAIP3 rs6920220 GG rituximab efficacy no No significant association was seen between genotype and whether a patient was a "responder" or a "non-responder". "Responders" had a post-rituximab disease activity score (DAS28) of lower than 5.1 and a DAS28 variation between baseline and post-treatment higher than 0.6. Genotype GG is not associated with response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. 22129793 982047118
TNFAIP3 rs2230926 T adalimumab efficacy yes Allele T is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele G. 28639493 1448633692
TNFAIP3 rs610604 GG adalimumab efficacy no Response was based on the change in PASI score before and after 3 months of treatment. PASI = psoriasis area and severity index. Genotype GG is not associated with response to adalimumab in people with Psoriasis as compared to genotype TT. 27564082 1448263959
TNFAIP3 rs610604 GG ustekinumab efficacy no No significant difference in the percentage of patients who responded to treatment with ustekinumab (i.e. a 75% reduction in The Psoriasis Area and Severity Index (PASI) score from baseline) was seen between the two genotypes, after 12 weeks of treatment. Genotype GG is not associated with response to ustekinumab in people with Psoriasis as compared to genotype TT. 23521149 1184168650
TNFAIP3 rs610604 GG etanercept efficacy no Response was based on the change in PASI score before and after 3 months of treatment. PASI = psoriasis area and severity index. Genotype GG is not associated with response to etanercept in people with Psoriasis as compared to genotype TT. 27564082 1448263953
TNFAIP3 rs610604 GG ustekinumab efficacy no Response was based on the change in PASI score before and after 3 months of treatment. PASI = psoriasis area and severity index. Differences for the CT group were not statistically significant. Genotype GG is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype TT. 27564082 1448263941
TNFAIP3 rs610604 GG + GT Tumor necrosis factor alpha efficacy yes Patients with the GG or GT genotypes had increased European Quality of life Visual Analog Scale (EQ-VAS) scores after 3 months of treatment. Please note that alleles have been complemented to the positive strand. Genotypes GG + GT are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic or Psoriasis as compared to genotype TT. 30653751 1450933031
TNFAIP3 rs6920220 AA Tumor necrosis factor alpha efficacy yes Patients with the AA genotype had decreased European Quality of life Visual Analog Scale (EQ-VAS) scores after 3 months and 6 months of treatment. Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic or Psoriasis as compared to genotypes AG + GG. 30653751 1450933039
TNFAIP3 rs6927172 CG + GG Tumor necrosis factor alpha efficacy yes Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD and UC cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation. Genotypes CG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype CC. 24776844 1296666850